The Company

History & Focus

HISTORY & FOCUS

Brain Neurotherapy Bio, Inc (BrainNeuBio) was established in 2018 by Krystof S. Bankiewicz, MD, PhD in association with the founders of Asklepios Biotherapeutics (AskBio), Sheila Mikhail, JD, MBA and R. Jude Samulski, PhD.

BrainNeuBio is a startup biotechnology company that focuses on the development of preclinical and early stage clinical neurotrophic factor gene therapies and associated technologies for the treatment of Parkinson’s disease and other neurological conditions.

BrainNeuBio’s initial developmental focus is advancing the safety and establishing preliminary efficacy measures related to glial cell line-derived neurotrophic factor (GDNF) gene therapy for Parkinson’s disease. This program utilizes the clinically-proven AAV2 gene transfer platform, delivered within the brain via precise convection-enhanced delivery (CED) methods.

LEADERSHIP TEAM

Founder and CEO, BrainNeuBio

Chief Operating Officer

Vice President, Clinical Affairs

Senior Director, Clinical Affairs

Associate Director, Clinical Studies

Associate Director, Clinical Operations

SCIENTIFIC FOUNDERS

Professor, Department of Neurological Surgery, Gilbert and Kathryn Mitchell Endowed Chair, The Ohio State University Professor, Department of Neurological Surgery, University of California San Francisco

Chair, Department of Neurological Surgery, The Ohio State University

Distinguished Professor of Neurology, University of California Irvine

BOARD OF DIRECTORS

 

News

Brain Neurotherapy Bio, Inc. Announces Treatment of First Patient in New GDNF Gene
Therapy Trial for Parkinson’s Disease

Posted:

COLUMBUS, OHIO and OAKLAND, CALIFORNIA, August 25, 2020 - - Brain Neurotherapy Bio, Inc. (BNB), a clinical stage biotechnology company focused on advancing central nervous system gene therapies for neurological disorders, today announced treatment of the first Parkinson’s disease patient in a Phase 1b glial cell line-derived neurotrophic factor (GDNF) gene therapy study.

Stem Cell Agency Approves Funding for Clinical Trials Targeting Parkinson’s Disease and Blindness

Posted:

Oakland, CA – The governing Board of the California Institute for Regenerative Medicine (CIRM) today invested $32.92 million to fund the Stem Cell Agency’s first clinical trial in Parkinson’s disease (PD), and to support three clinical trials targeting different forms of vision loss.

 
brain-neurotherapy-bio-logo.png

Brain Neurotherapy Bio, Inc. Copyright © 2020. All Rights Reserved